INNT - Innovate Biopharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 531.02M
Enterprise Value 322.71M
Trailing P/E N/A
Forward P/E 1-1.47
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)6.17
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-1.68

Trading Information

Stock Price History

Beta (3Y Monthly) -2.64
52-Week Change 3-84.17%
S&P500 52-Week Change 32.33%
52 Week High 39.6780
52 Week Low 30.7280
50-Day Moving Average 31.0232
200-Day Moving Average 31.5484

Share Statistics

Avg Vol (3 month) 3293.32k
Avg Vol (10 day) 3319.72k
Shares Outstanding 5N/A
Float 23.7M
% Held by Insiders 143.23%
% Held by Institutions 110.70%
Shares Short (Jul 31, 2019) 41.59M
Short Ratio (Jul 31, 2019) 410.46
Short % of Float (Jul 31, 2019) 45.42%
Short % of Shares Outstanding (Jul 31, 2019) 44.42%
Shares Short (prior month Jun 28, 2019) 41.73M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 210/1
Last Split Date 3Feb 1, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-65.93%
Return on Equity (ttm)-328.63%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -13.48M
Net Income Avi to Common (ttm)-13.91M
Diluted EPS (ttm)-0.4910
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)13.34M
Total Cash Per Share (mrq)0.37
Total Debt (mrq)4.11M
Total Debt/Equity (mrq)82.17
Current Ratio (mrq)1.51
Book Value Per Share (mrq)0.14

Cash Flow Statement

Operating Cash Flow (ttm)-16.64M
Levered Free Cash Flow (ttm)-8.72M